Genmab A (GMAB) Total Current Liabilities (2019 - 2026)
Genmab A's (GMAB) quarterly Total Current Liabilities came in at $1.2 billion in Q1 2026, down 17.45% on a QoQ basis from $1.4 billion in Q4 2025.
Genmab A (GMAB) Total Current Liabilities (2019 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Total Current Liabilities data on file, last reported at $1.2 billion in Q1 2026.
- Quarterly Total Current Liabilities changed N/A year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (changed N/A YoY) and the FY2025 annual result came in at $1.4 billion, up 91.8% from the prior year.
- Total Current Liabilities declined to $1.2 billion in Q1 2026, from $1.4 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $1.4 billion in Q4 2025 to a low of $368.0 million in Q4 2023.
- A 4-year average of $847.8 million and a median of $742.5 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities surged 102.17% — and 2025, when it soared 91.8%.
- Tracing GMAB's Total Current Liabilities over 4 years: stood at $368.0 million in 2023, then surged by 102.17% to $744.0 million in 2024, then soared by 91.8% to $1.4 billion in 2025, then decreased by 17.45% to $1.2 billion in 2026.
- The last three Total Current Liabilities figures came in at $1.2 billion (Q1 2026), $1.4 billion (Q4 2025), and $741.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 1.14 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Bn |
| Mar 31, 2026 | 1.18 Bn |
| Dec 31, 2025 | 1.43 Bn |
| Sep 30, 2025 | 741.00 Mn |
| Jun 30, 2025 | 629.00 Mn |
| Dec 31, 2024 | 744.00 Mn |
| Dec 31, 2023 | 368.00 Mn |
| Sep 30, 2020 | 2,258.00 |
| Dec 31, 2019 | 938.00 |
| Sep 30, 2019 | 654.77 Mn |